Mirae Company Supplies Surgical Robot 'Revo-i' to Queens Park Women's Hospital

From the left, Kim Jun-gu, CEO of Mirae Company, and Choi Jin-seok, Chief Director of Queens Park Women's Hospital.

[Asia Economy Reporter Jang Hyowon] Mirae Company (CEO Kim Jungoo) announced on the 9th that it has supplied the laparoscopic surgical robot Revo-i to Queens Park Women’s Hospital, a women’s specialty hospital. Following the successful export to Russia in August, the company is now supplying Revo-i to domestic hospitals as well.

Located in Haeundae, Busan, Queens Park Women’s Hospital is a women’s specialty hospital specializing in laparoscopic clinics for conditions such as endometriosis and uterine fibroids. It has recorded 5,000 cases of single-port laparoscopic surgery. The hospital is led by Dr. Choi Jinseok, a laparoscopic uterine fibroid specialist, and is staffed by numerous obstetrics and gynecology specialists. Queens Park Women’s Hospital is also known as a designated hospital for the US military in Korea, having passed the US military’s stringent procedures and strict screening processes.

Mirae Company places great significance on being the first in Korea to supply laparoscopic surgical robots to a women’s specialty hospital. Although the versatility of the surgical robot has already been proven through pre-approval clinical trials with the Ministry of Food and Drug Safety, in addition to its active use in general surgery at existing hospitals, its application in women’s specialty surgeries at Queens Park Women’s Hospital marks an opportunity to expand its indications.

Kim Jungoo, CEO of Mirae Company, stated, “Through this supply of Revo-i, it will be recognized that Revo-i enables precise surgeries not only in general surgeries such as prostatectomy, cholecystectomy, and appendectomy but also in gynecological surgeries.” He added, “The use of laparoscopic robotic surgery is expected to increase across various indications, and we plan to focus on expanding domestic and international sales through continuous increases in surgery numbers, expansion of indications, and active marketing.”

This content was produced with the assistance of AI translation services.